Federal Court Orders Preliminary Injunction on U.S. Sales of Medtronic's Infringing Transcatheter Valve
April 11 2014 - 7:07PM
Marketwired
Federal Court Orders Preliminary Injunction on U.S. Sales of
Medtronic's Infringing Transcatheter Valve
IRVINE, CA--(Marketwired - Apr 11, 2014) - Edwards Lifesciences
Corporation (NYSE: EW), the global leader in the science of heart
valves and hemodynamic monitoring, announced that the U.S. District
Court for the District of Delaware today granted a preliminary
injunction limiting the sale of Medtronic's CoreValve system in the
United States. The court ordered the injunction to go into effect
in seven business days. Today's hearing related to a federal
jury decision in 2010 that CoreValve willfully infringes Edwards'
U.S. Andersen transcatheter aortic valve replacement patent.
At the conclusion of the hearing, Chief Judge Gregory Sleet
ordered Edwards and Medtronic to confer on what instances the
CoreValve device could continue to be used in the treatment of U.S.
patients at centers currently trained on CoreValve. There is a
large body of evidence demonstrating the safety and performance of
the Edwards SAPIEN valves, and the company remains committed to
ensuring patients have appropriate access to transcatheter
therapy.
Background This
case was initiated by Edwards in 2008. On April 1, 2010, a federal
jury found Medtronic willfully infringed Edwards' U.S. Andersen
patent and awarded damages. In Nov. 2012, the U.S. Court of
Appeals for the Federal Circuit affirmed the jury decision; in Oct.
2013, the U.S. Supreme Court declined to hear Medtronic's
appeal.
The patent involved in this suit is part of the Andersen family
of patents. The U.S. Andersen patent was issued in 1995. A petition
has been filed with the U.S. Patent and Trademark Office to extend
this patent into early 2016.
In a separate case, a federal jury in January found that
Medtronic CoreValve had willfully infringed Edwards' U.S. Cribier
transcatheter heart valve patent, and awarded damages to Edwards in
that trial.
About Edwards
Lifesciences Edwards Lifesciences is the global leader in
the science of heart valves and hemodynamic monitoring. Driven
by a passion to help patients, the company partners with clinicians
to develop innovative technologies in the areas of structural heart
disease and critical care monitoring, enabling them to save and
enhance lives. Additional company information can be found at
www.edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo and SAPIEN
are trademarks of Edwards Lifesciences Corporation. All other
trademarks are the property of their respective owners.
Media Contact: Sarah Huoh 949-250-5070 Investor Contact: David
K. Erickson 949-250-6826
Edwards Lifesciences (NYSE:EW)
Historical Stock Chart
From Mar 2024 to Apr 2024
Edwards Lifesciences (NYSE:EW)
Historical Stock Chart
From Apr 2023 to Apr 2024